美股異動 | Walgreens(WBA.US)跌近6% 市場憂慮疫情過後公司增長放緩
格隆匯3月31日丨Walgreens(WBA.US)現跌5.92%,報44.65美元,總市值385億港元。Walgreens公佈截至2月28日的2022第二財季業績,調整後每股收益為1.59美元,高於上年同期的1.40美元,分析師預計每股收益為1.40美元;季度銷售額為337.6億美元,高於去年同期的327.8億美元,分析師預計為333.3億美元;該公司重申了其對2022財年調整後每股收益低至個位數增長的前景,分析師預計每股收益為5.02美元。由於市場新冠疫苗的需求,銷售額增長了7.3%。但市場分析稱,投資者憂慮疫情過後公司增長放緩。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.